Mycophenolate mofetil treatment for primary glomerular diseases
نویسندگان
چکیده
منابع مشابه
Mycophenolate mofetil in chronic glomerular diseases.
Correspondence: Helena Sá [email protected] Hospital da Universidade de Coimbra. Praceta Mota Pinto 3000-075 Coimbra. Portugal INTRODUCTION Mycophenolate mofetil (MMF), the first pharmaceutical prodrug of mycophenolic acid (MPA) that received approval for human clinical use, has been utilised in solid organ transplantation since 1995, particularly in kidney transplantation. MMF launchin...
متن کاملMycophenolate mofetil in the treatment of glomerular diseases.
AIM Treatment of primary glomerular diseases may be unsuccessful or have potential toxicities. Mycophenolate mofetil (MMF) is a new, relatively non-toxic drug. It has been introduced as an immunosuppressive drug, but it also has effects on non-immune cells (vascular smooth muscle cells, fibrocytes). Therefore, we evaluated the use of MMF for the treatment of glomerular diseases at different sta...
متن کاملMycophenolate mofetil treatment in resistant myositis.
OBJECTIVES To assess the efficacy and tolerability of mycophenolate mofetil (MMF) in six patients with myositis refractory to conventional immunosuppressive therapy. METHODS Six patients were identified from hospital notes. All had previously failed to respond to other immunosuppressive treatments. Efficacy was measured as changes in muscle strength, creatine kinase (CK) levels and prednisolo...
متن کاملTreatment of lupus nephritis by mycophenolate mofetil.
BACKGROUND/AIMS Mycophenolate mofetil (MMF) has been increasingly used for the treatment of lupus nephritis (LN). The aim of this study was to examine the efficacy and safety of MMF used with low doses of corticosteroids as maintenance therapy in patients with LN. METHODS The study covered 35 patients, most of them with proliferative types of LN (5 WHO class III, 26 class IV), while 1 had cla...
متن کاملMycophenolate mofetil for primary focal segmental glomerulosclerosis: systematic review.
BACKGROUND Current treatments for primary focal segmental glomerulosclerosis (FSGS), including corticosteroids and cyclosporine, are not satisfactory for all patients and may induce significant side effects. Antidotal benefits of mycophenolate mofetil (MMF) as an add-on to these immunosuppressive therapies have been reported. This review aims to systematically summarize the efficacy and safety ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kidney International
سال: 2002
ISSN: 0085-2538
DOI: 10.1046/j.1523-1755.2002.00214.x